Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IDX320 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| IDX320 + PBO → IDX320 + IDX184 | EXPERIMENTAL | 400 mg IDX320 and IDX184 matching placebo (PBO) once daily for 7 days; followed by 400 mg IDX320 and 100 mg IDX184 once daily for 7 days |
| IDX184 + PBO → IDX184 + IDX320 | EXPERIMENTAL | 100 mg IDX184 and IDX320 matching PBO for 7 days; followed by 100 mg IDX184 and 400 mg IDX320 for 7 days |
| IDX320 PBO + IDX184 PBO | PLACEBO_COMPARATOR | IDX320 matching PBO + IDX184 matching PBO for 14 days |
| Name | Type | Description |
|---|---|---|
| IDX320 | DRUG | IDX320 400 mg in tablets (8x50 mg) administered orally once daily |
| IDX184 | DRUG | IDX184 100 mg in capsules (2x50 mg) administered orally once daily |
| IDX184 placebo | DRUG | IDX184 matching placebo in capsules administered orally once daily |
| IDX320 placebo | DRUG | IDX320 matching placebo in tablets administered orally once daily |
Inclusion Criteria: To participate in the study, participants must meet the following requirements: 1. Must be a healthy male or female between 19 and 65 years of age with body mass index (BMI) between 18 and 35 kg/m2. 2. Must be a non-smoker. 3. Must agree to use an acceptable double-barrier meth...
IDX320 is an investigational small molecule being developed for the treatment of Chronic Hepatitis C. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
IDX320 is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
IDX320 is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The drug is being studied for its potential use in treating Chronic Hepatitis C.
IDX320 has one completed clinical trial, NCT01157104, which was a Phase 1 drug-drug interaction study evaluating the combination of IDX320 and IDX184 in healthy participants. The trial enrolled 20 participants and was placebo-controlled and double-blind.
IDX320 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Chronic Hepatitis C. The drug has not yet completed the clinical trials necessary to support a marketing application.